Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

FDA vs. Pentagon: U.S. House Passes Fix to Defense Bill’s Drug Approval Provision

Washington, DC, November 17, 2017 — Rebecca Kheel reports in The Hill that the U.S. House on Wednesday, November 15 passed by voice vote a bill to speed up Food and Drug Administration (FDA) approval of medical devices and drugs to be used on the battlefield.

The bill is meant to address a controversial provision of the annual defense policy bill passed by the House on Tuesday that would allow the Pentagon to sign off on unapproved devices and drugs.

“Our men and women in uniform have put their lives on the line for this country, and they deserve to have the earliest possible access to medical products that could save their lives on the battlefield,” Energy and Commerce Committee Chairman Greg Walden (R-Ore.) said on the House floor Wednesday. “We found a good balance with our friends on the Armed Services Committee, and in working with the FDA and the leadership of the Pentagon.” Continue reading

Bill Gates Investing $50 Million to Help Alzheimer’s Research — And It’s Personal

Bill Gates

Seattle, WA, November 16, 2017 — Lindsey Bever reports in The Washington Post that Bill Gates is personally investing $50 million to help fund research to find a treatment for Alzheimer’s disease, a type of dementia Gates says has struck members of his own family.

There is no cure for Alzheimer’s, which destroys memory and other mental processes, so Gates said he is investing his own money in the Dementia Discovery Fund, a private-public partnership to search for a solution.

“It’s a terrible disease that devastates both those who have it and their loved ones,” the philanthropist wrote on November 13 on his blog. Continue reading

TODAY @ 5 PM: Event: HINJ and Rutgers Biomedical Engineering Medical Device Development Center to Host ‘Patient Perspectives’ in Research on November 16; Third in Forum Series

New Brunswick, NJ, November 16, 2017 — Please join the Rutgers Biomedical Engineering Medical Device Development Center and the HealthCare Institute of New Jersey (HINJ) on Thursday, November 16 for “The Patient’s Perspective: Emotional and Physical Benefits of Medical Devices,” the third in the Rutgers-HINJ Fall 2017 series of educational panels and seminars that focus on the medical device industry.

The event will be held from 4:30 to 7:00 p.m. (networking at 4:30 p.m.; program at 5:30 p.m.) at Rutgers University BME Auditorium (Busch Campus), 599 Taylor Road, Piscataway.

Scientists and engineers do amazing work creating innovative therapies and devices that enhance and save lives.  However, while working in a lab, there are few opportunities to see patients who benefit from the health care made possible by medical innovation.  Continue reading

Opinion: New Jersey Is Headed for 21st Century with Gov.-Elect Phil Murphy

Governor-Elect Phil Murphy

Washington, DC, November 15, 2017 — The Hill published the following opinion piece by Douglas Singleterry and Zenon Christodoulou on November 11:

New Jersey Gov.-elect Phil Murphy grew up several miles southwest of Kendall Square.  With proximity to MIT, this section of Cambridge has been hailed as the “most innovative square mile on the planet” due to the number of tech startups.

Last year, a study confirmed that Boston rivals Silicon Valley as the nation’s premier location for digital innovation.  “Before Silicon Valley, there was New Jersey,” Murphy reminded Garden State voters throughout the gubernatorial election.   Continue reading

Trump Selects Alex Azar to Serve as Secretary of Health and Human Services

Alex Azar

Washington, DC, November 14, 2017 — President Donald J. Trump yesterday announced his nomination of Alex Azar, a former pharmaceutical executive and a top health official during the George W. Bush administration, to lead the U.S. Department of Health and Human Services.

In announcing that he is nominating Azar to be secretary of the government’s largest civilian department, the president turned to a health policy insider and conservative thinker.

Azar spent a decade at Eli Lilly and Co., including five years as president of Lilly USA, its biggest affiliate, before stepping down in January to work as a health-care consultant. Continue reading

Full List of Gov.-Elect Phil Murphy’s Transition Committees and Co-Chairs Named

Governor-Elect Phil Murphy

Trenton, NJ, November 13, 2017 — Governor-elect Phil Murphy on Monday released the full list of transition committees and co-chairs that will help him as he prepares to take over the front office in January.

The majority of transition leaders and co-chairs are women or represent minority communities, according to a news release from his spokesman.

“I pledged to build my administration to mirror the diversity, talent, and potential of New Jersey, and my transition will be no different,” Murphy said in the release. Continue reading

Rutgers-Led Research May Lead to New Treatments for Neurodegenerative Diseases and Nerve Injuries

Robert O’Hagan

New Brunswick, NJ, November 13, 2017 — Todd B. Bates reports that inside cells, protein “motors” act like trucks on tiny cellular highways to deliver life-sustaining cargoes.

Now a team led by Rutgers University–New Brunswick researchers has discovered how cells deploy enzymes to place traffic control and “roadway under construction” signs along cellular highways.

“To stay alive and function, every cell in our body needs to transport cargoes to the place they’re needed inside the cell, in the right amount and at the right time,” said Robert O’Hagan, lead author of a new study and assistant research professor in the Human Genetics Institute of New Jersey and the Department of Genetics at Rutgers University–New Brunswick. Continue reading

Morris County Economic Development Corp. Hosts ‘Growth and Innovation Forum’

Parsippany, NJ, November 13, 2017 — TapInto reports that the Morris County Economic Development Corporation on November 3 hosted it annual Growth and Innovation Forum at the Sheraton Parsippany where a full house of business leaders learned about the latest developments in Innovation strategies throughout the region.

The keynote speaker was John Stecher, the Chief Innovation Officer of Barclays Capital who spoke about the importance of community in technology innovation and business growth.

Also presenting was Aaron Price, Founder & CEO of Propelify which is a mostly online community of innovators, entrepreneurs, and technologists who empower each other with the tools, knowledge, and people to turn ideas into action. Continue reading

NJ Launches ’65 by ’25: Many Paths One Future’ Campaign; Higher Ed, Labor, Educators Partner with Business for Competitive, Innovative and Prosperous State

Princeton, NJ, November 12, 2017 — More than 100 education, business and industry leaders took part in the official launch in September of New Jersey’s 65 by ’25: Many Paths, One Future campaign at the Robert Wood Johnson Foundation Headquarters in Princeton.

With the pace of innovation rapidly accelerating, New Jersey must provide real economic opportunities for residents by supporting and creating pathways for everyone to acquire the skills and education that will help them secure rewarding careers.

According to the latest data available, 50.2 percent of New Jersey’s workers have some level of education or training beyond high school — well short of the 65 percent economists say will be needed by 2025 to meet the demand for a skilled labor workforce equipped with high-quality, industry-valued post-secondary credentials. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, November 11, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a September report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading